Medtronic, Inc. has announced that the High Court in Seoul, Korea has found that the balloon kyphoplasty device made by Taeyeon Medical Co., Ltd. infringes a valid Medtronic patent and has ordered destruction of Taeyeon's stock of the infringing device and related manufacturing equipment.

"We are pleased by the High Court's ruling," said Alex DiNello, vice president and general manager of the Kyphon Products Division of Medtronic, which markets Kyphon® Balloon Kyphoplasty for the treatment of vertebral compression fractures. "We have solid patents protecting our kyphoplasty products, and we are committed to vigorously defending our intellectual property."

Taeyeon brands impacted by this legal decision are Typhoon and Balex. The product and manufacturing equipment destruction order was enforced on October 12, 2010 by bailiffs of the Korean court. Taeyeon is appealing the decision to the Korean Supreme Court.

About Kyphon Balloon Kyphoplasty

During the minimally invasive Kyphon Balloon Kyphoplasty procedure, a needle and tube are used to create a small pathway into the fractured bone, generally on both sides of the vertebral body. Orthopedic balloons are inserted and then inflated inside the fractured bone in an attempt to reduce the fracture. Inflation of the balloons creates cavities in the vertebral body that are filled with bone cement, forming an "internal cast" to support the surrounding bone and stabilize the fracture.

The complication rate with Kyphon Balloon Kyphoplasty has been demonstrated to be low. There are risks associated with the procedure (e.g., cement leakage), including serious complications, and though rare, some of which may be fatal. This procedure is not for everyone. A prescription is required. Patients should consult their physicians for a complete list of indications, contraindications, benefits, and risks. Only patients and their physicians can determine whether this procedure is right for a particular patient.

Source:
Medtronic, Inc.